Inclusion Criteria:

- Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB
with pleural effusion) and/or metastatic (stage IV) NSCLC

- Progression to first-line therapy for advanced/metastatic NSCLC

- Bi-dimensionally measurable disease (not included in radiation field)

- ECOG performance status of 0-2

- Life expectancy of more than 6 months

- Adequate liver (serum bilirubin <1.5 times the upper normal limit, AST and ALT <2.5
times the upper normal limit in the absence of demonstrable liver metastases, or <5
times the upper normal limit in the presence of liver metastases,adequate renal
function (serum creatinine <1.5 times the upper normal limit),and bone marrow
(neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function

- Signed informed consent

Exclusion Criteria:

- Central nervous system involvement (unless if the patient has being previously
irradiated and is clinically stable)

- Presence of a centrally located mass or a tumor mass in close relation to large
vessels or a mass with cavitation.

- Surgery or radiation therapy within the last 14 days from study entry

- Active infection

- History of life-threatening hemoptysis / hematemesis, history of thrombosis or use of
anti-coagulation therapy

- History of significant cardiac disease (unstable angina, congestive heart failure,
myocardial infarction, ventricular arrhythmias) or stroke within the previous 6
months or uncontrolled hypertension

- Patients on other experimental treatment protocols

- History of a second primary malignancy (other than basal-cell skin carcinoma or in
situ carcinoma of the cervix)

- Psychiatric illness or social situation that would preclude study compliance

- Pregnant or lactating women